로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Antibody > TNF-alpha > TNA-AM493

Monoclonal Anti-TNF-alpha Antibody, Human IgG1 (13B8)

  • Source
    Monoclonal Anti-TNF-alpha antibody, Human IgG1 (13B8) is a chimeric monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with TNF-alpha.
  • Isotype
    Human IgG1 | Kappa
  • Specificity
    This product is a specific antibody specifically reacts with TNF-alpha.
  • Application
    ELISA
  • Purity

    >95% as determined by SDS-PAGE.

  • Endotoxin
    Less than 1.0 EU per mg by the LAL method.
  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS,pH 7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
TNF-alpha SDS-PAGE

Monoclonal Anti-TNF-alpha antibody, Human IgG1 (13B8) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-Elisa
 TNF-alpha ELISA

ImmobilizedHuman TNF-alpha Protein, His Tag (active trimer) (MALS verified) (Cat. No. TNA-H5228) at 2μg/mL (100μL/well) can bind Monoclonal Anti-TNF-alpha antibody, Human IgG1 (13B8) (Cat. No. TNA-AM493) with a linear range of 0.05-1.56 ng/mL (QC tested).

Bioactivity-SPR
 TNF-alpha SPR

Monoclonal Anti-TNF-alpha antibody, Human IgG1 (13B8) (Cat. No. TNA-AM493) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TNF-alpha, His Tag (Cat. No. TNA-H5228) with an affinity constant of 0.133 nM as determined in a SPR assay (Biacore 8K) (Routly tested).

Bioactivity-BLI
 TNF-alpha BLI

Loaded Monoclonal Anti-TNF-alpha antibody, Human IgG1 (13B8) (Cat. No. TNA-AM493) on Protein A Biosensor, can bind Human TNF-alpha, His Tag (active trimer) (MALS verified) (Cat. No. TNA-H5228) with an affinity constant of 1.03 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

 TNF-alpha BLI

Loaded Monoclonal Anti-TNF-alpha antibody, Human IgG1 (13B8) (Cat. No. TNA-AM493) on Protein A Biosensor, can bind Human TNF-alpha, premium grade (MALS verified) (Cat. No. TNA-H4211) with an affinity constant of 2.97 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

 TNF-alpha BLI

Loaded Monoclonal Anti-TNF-alpha antibody, Human IgG1 (13B8) (Cat. No. TNA-AM493) on Protein A Biosensor, can bind Canine TNF-alpha, His Tag (Cat. No. TNA-C52H3) with an affinity constant of 2.24 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

  • Background
    Tumor necrosis factor alpha (TNFα) is a cytokine produced primarily by monocytes and macrophages. It is found in synovial cells and macrophages in the tissues.The primary role of TNFα is in the regulation of immune cells. TNFα is able to induce apoptotic cell death, to induce inflammation, and to inhibit tumorigenesis and viral replication. Dysregulation of TNFα production has been implicated in a variety of human diseases, including major depression, Alzheimers disease and cancer. Recombinant TNFα is used as an immunostimulant under the INN tasonermin. TNFα can be produced ectopically in the setting of malignancy and parallels parathyroid hormone both in causing secondary hypercalcemia and in the cancers with which excessive production is associated.
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 450,000

가격(KRW) : 2,970,000

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs:61 Details
  • Number of Drugs in Clinical Trials:63 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

DMF 신청
DMF (Drug Master File)

관련 제품

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop